The General Assembly of Pherecydes Pharma Approves the Evolution of Its Governance Towards a Company with a Board of Directors
The new Board of Directors has appointed Didier Hoch as Chairman and CEO, and Thibaut du Fayet as Deputy CEO
Regulatory News:
Pherecydes Pharma (FR0011651694 - ALPHE, éligible PEA-PME) (Paris:ALPHE), a biotech company specializing in precision phage therapy for the treatment of resistant and/or complicated bacterial infections, announces that the Combined General Meeting (AGM) held on May 19, 2022 was able to deliberate, the quorum having been reached.
The AGM adopted all the proposed resolutions, with the exception of resolution 23, which was rejected, in accordance with the Board's recommendations.
In particular, the company's shareholders approved the change in the company's management and administration by adopting a Board of Directors and a General Management.
The current members of the Supervisory Board were appointed as the first directors of Pherecydes Pharma.
The Board of Directors is thus composed of 7 members, 2 of whom are independent.
At the end of the AGM, the Board of Directors adopted the following decisions:
- the Board of Directors has taken note of the termination of the functions of Mr. Guy-Charles Fanneau de La Horie, previously Chairman of the Executive Board, who did not wish, for personal reasons, to assume the mandate of CEO in the new governance;
- consequently, and contrary to what had been announced, the Board has not decided to adopt, at this stage, a separation of the functions of CEO and Chairman of the Board of Directors;
- Mr. Didier Hoch, previously Chairman of the Supervisory Board, has been appointed Chairman and CEO; and
- Mr. Thibaut du Fayet, previously member of the Executive Board, was appointed Deputy CEO.
The Board of Directors thanks Mr. Guy-Charles Fanneau de La Horie who has been one of the driving forces in the development of the company both on the operational and financial levels, notably with the successful IPO of the company in 2021. It is envisaged at this stage that Mr. Guy-Charles Fanneau de La Horie will contribute, on a transitional basis, his expertise within the framework of a service contract, the terms of which remain to be determined.
It is also envisaged to adopt, at a later stage, a separation of the functions of Chairman of the Board of Directors and CEO and thus to appoint a new CEO.
Pherecydes Pharma would like to thank all shareholders present, represented or voting by post for their commitment and support.
The consolidated result of the vote by resolution and the minutes of the AGM of May 19, 2022 will be available on the Company's website, under Shareholders / General Meetings, within the legal deadlines.
About Pherecydes Pharma
Founded in 2006, Pherecydes Pharma is a biotechnology company that develops treatments against resistant bacterial infections, responsible for many serious infections. The Company has developed an innovative approach, precision phage therapy, based on the use of phages, natural bacteria-killing viruses. Pherecydes Pharma is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two thirds of hospital-acquired resistant infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The concept of precision phage therapy has been successfully applied in several dozen patients in the context of compassionate use, under the supervision of the French National Agency for the Safety of Medicines (ANSM). Headquartered in Nantes, Pherecydes Pharma has a team of around twenty experts from the pharmaceutical industry, biotechnology sector and academic research.
For more information, www.pherecydes-pharma.com
Disclaimer
This press release contains non-factual elements, including, but not limited to, certain statements regarding future results and other future events. These statements are based on the current vision and assumptions of the management of the Company. They incorporate known and unknown risks and uncertainties that could result in significant differences in results, profitability and expected events. In addition, Pherecydes Pharma, its shareholders and its affiliates, directors, officers, counsels and employees have not verified the accuracy of, and make no representations or warranties about, statistical information or forecast information contained within this news release and that originates or is derived from third party sources or industry publications; these statistical data and forecast information are only used in this press release for information purposes. Finally, this press release may be drafted in French and in English. In the event of differences between the two texts, the French version will prevail.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005800/en/
Pherecydes Pharma
Thibaut du Fayet
Deputy CEO
investors@pherecydes-pharma.com
NewCap
Dusan Oresansky
Investor Relations
pherecydes@newcap.eu
T.: +33 1 44 71 94 92
NewCap
Arthur Rouillé
Media Relations
pherecydes@newcap.eu
T.: +33 1 44 71 00 15
